LY6K and breast cancer: In clinical samples, LY6K mRNA expression was significantly higher in the 91 BC samples than in the 37 NBE samples (BC: mean 19.6±3.6, 95% CI 12.4–26.8; NBE 2.4±0.6, 95% CI 1.0–3.7; P<0.0001; Figure 2B).